Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.36 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7903773 | 1.00 | PYGL (0.38) | PYGLFOLH1LMNAKMT2AKDM4E | |
| SCHEMBL4469539 | 0.82 | LMNA (0.49) | FOLH1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL7902705 | 0.82 | LMNA (0.49) | FOLH1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL8812961 | 0.80 | BCHE (0.40) | KMT2AALDH1A1HPGD | |
| SCHEMBL8511435 | 0.80 | BCHE (0.40) | KMT2AALDH1A1HPGD | |
| SCHEMBL7900456 | 0.80 | FOLH1 (0.48) | FOLH1LMNANAALAD2RIMKLAGAA | |
| SCHEMBL8722086 | 0.80 | CA2 (0.42) | PYGLFOLH1CA12CA1CA2 | |
| SCHEMBL8722067 | 0.78 | CA1 (0.47) | LMNAALDH1A1CA12CA1CA2 | |
| SCHEMBL8726467 | 0.78 | CA2 (0.41) | PYGLFOLH1CA12CA1CA2 | |
| SCHEMBL8722082 | 0.78 | CA1 (0.42) | PYGLFOLH1ALDH1A1HPGDCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6277880-B1 | ANTIBODY DIRECTED ENZYME PRODUG THERAPY | ZENECA LIMITED (GB) | 2001-08-21 | — | — | US | disclosed |
| US-5958971-A | PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION | ZENECA LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| EP-0651740-B1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LTD (GB) | 1998-10-21 | — | — | EP | disclosed |
| US-5714148-A | PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| US-5660829-A | DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE | ZENECA LIMITED (GB) | 1997-08-26 | — | — | US | disclosed |
| US-5587161-A | TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME | ZENECA LIMITED (GB) | 1996-12-24 | — | — | US | disclosed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |